WithdrawnPhase 3

A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030)

Stopped: Withdrawn for administrative reasons

0Started 2008-09

Plain-language summary

The purpose of this study is to investigate the effects of MK0822 in prolonging the time to first bone metastasis in men with castration-resistant prostate cancer.

Who can participate

Age range18 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. currently is receiving a bisphosphonate or other drug therapy for osteoporosis
✕. has been treated with an oral bisphosphonate for osteoporosis for more than 3 months within the 2 years prior to Visit 1, or for a total of more than 6 months at any time prior to Visit 1
✕. has been treated with an intravenous bisphosphonate within the 12 months prior to Visit 1

What they're measuring

To assess the effect of treatment with MK0822 5 mg once daily on bone metastasis-free survival (i.e., the risk of developing a first bone metastasis or dying from any cause) compared to placebo

Timeframe: Approximately 36 months (event-driven study)

Trial details

NCT IDNCT00691899

SponsorMerck Sharp & Dohme LLC

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2008-09

View on ClinicalTrials.gov More Prostate Cancer trials